At OsNovum, we are pioneering a precision approach to develop regenerative therapies designed to transform the lives of patients with osteoporotic conditions. While there are many drugs available on the market for osteoporosis treatment, they frequently cause significant side effects and patients often refuse treatment to avoid those adverse systemic effects. Our solution approaches the treatment of weak and frail bone in a very different manner.
Our technology has been FDA-cleared and on the market for years regenerating maxillofacial bone thanks to decades of vigorous research and development offered by our founders through SteinerBio. OsNovum is now taking this regenerative material, which converts poorly mineralized bone into dense, healthy tissue, to the skeleton through a local application into an areas of weakened bone.
OsNovum is adopting this innovative technology to address osteoporosis and regenerate weakened bones before they have a chance to fracture, creating a lasting impact on so many lives.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 1051 Olsen St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.osnovum.com
- HQ
- Henderson, Nevada
Osnovum Questions
Osnovum's website is http://www.osnovum.com
Osnovum's LinkedIn profile is https://www.linkedin.com/company/osnovum
Osnovum has
2 employees.
View email and phone details for 2
employees at Osnovum.
Osnovum's industry is
Biotechnology Research
Osnovum's top competitors are
Steinerbio,
Barreleye,
Mister Advertising - Consulting And Advertising Agency,
Embr,
Paladin Power Inc,
Fragility Fracture Network (Ffn),
National Debt Bureau,
Conceptra Biosciences,
Makescents.com.au,
Embr Group.
Osnovum's categories are Biotechnology Research
Osnovum's founding year is 2020
